Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Xience v. Cypher "The unrestricted use of everolimus-eluting stents appears to be associated with improved clinical long-term outcome compared with sirolimus-eluting stents," Swiss researchers concluded from data presented Aug. 30 at the European Society of Cardiology annual conference in Stockholm. Using propensity score matching, the study retrospectively compared clinical outcomes from 1,342 pairs of patients treated with Abbott's Xience or Johnson & Johnson's Cypher. The composite endpoint of death, myocardial infarction and target vessel revascularization occurred in 14.9% of Xience patients and 18% of Cypher patients after up to three years of follow-up
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.